Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression

By He Suqin   Zhang Chaohua   Shafi Ayesha A.   Sequeira Manuel   Acquaviva Jaime   Friedland Julie C.   Sang Jim   Smith Donald L.   Weigel Nancy L.   Wada Yumiko   Proia David A.  

International Journal of Oncology, Vol. 42, Iss. 1, 2013-01 ,pp. : 35-43

Spandidos Publications

Access to resources Recommend Favorite

HSP90: a rising star on the horizon of anticancer targets

By Whitesell Luke   Dai Chengkai  

Future Oncology, Vol. 1, Iss. 4, 2005-08 ,pp. : 529-540

Future Medicine

Access to resources Recommend Favorite

Novel Molecular Targets in Cancer Chemotherapy Waiting for Discovery

By  

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 4, Iss. 5, 2004-09 ,pp. : 421-423

Bentham Science Publishers

Access to resources Recommend Favorite

Heat shock protein 90 (Hsp90) chaperone complex inhibitor, Radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor

By Harashima K   Akimoto T   Nonaka T   Tsuzuki K   Mitsuhashi N   Nakano T  

International Journal of Radiation Biology, Vol. 81, Iss. 1, 2005-01 ,pp. : 63-76

Informa Healthcare

Access to resources Recommend Favorite

Novel C-Terminal Hsp90 Inhibitor for Head and Neck Squamous Cell Cancer (HNSCC) with in vivo Efficacy and Improved Toxicity Profiles Compared with Standard Agents

By Cohen Stephanie   Mukerji Ridhwi   Samadi Abbas   Zhao Huiping   Blagg Brian   Cohen Mark  

Annals of Surgical Oncology, Vol. 19, Iss. 3, 2012-07 ,pp. : 483-490

Springer Publishing Company

Access to resources Recommend Favorite